Published in J Gastroenterol Hepatol on February 01, 2006
Monitoring during and after antiviral therapy for hepatitis B. Hepatology (2009) 0.91
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int (2008) 0.86
Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virol J (2013) 0.83
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol (2012) 2.43
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology (2006) 2.05
Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol (2006) 2.04
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer (2010) 1.92
Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol (2013) 1.86
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol (2004) 1.82
Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther (2011) 1.65
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol (2012) 1.63
Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. Int J Radiat Oncol Biol Phys (2009) 1.63
Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett (2004) 1.63
Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2010) 1.51
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology (2011) 1.48
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res (2008) 1.45
Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010. Dig Dis Sci (2014) 1.43
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer (2008) 1.40
[In vitro culture of hepatitis C virus (HCV) using immortalized hepatocyte]. Korean J Gastroenterol (2008) 1.39
Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys (2010) 1.36
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett (2011) 1.33
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol (2006) 1.26
HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med (2005) 1.20
Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci (2005) 1.18
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (2006) 1.18
Emerging need for vaccination against hepatitis A virus in patients with chronic liver disease in Korea. J Korean Med Sci (2007) 1.18
Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer (2013) 1.16
Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol (2011) 1.15
Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol (2012) 1.14
SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis (2010) 1.13
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol (2011) 1.13
Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine (2012) 1.12
Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}. J Biol Chem (2010) 1.12
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res (2004) 1.12
A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem (2010) 1.09
Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys (2008) 1.09
A case of acute cholestatic hepatitis associated with the seeds of Psoralea corylifolia (Boh-Gol-Zhee). Clin Toxicol (Phila) (2005) 1.06
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2009) 1.06
Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett (2011) 1.05
Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf (2012) 1.05
Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol (2004) 1.05
Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients. Yonsei Med J (2009) 1.04
Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol (2005) 1.03
Monitoring the antiviral effect of alpha interferon on individual cells. J Virol (2007) 1.03
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer (2012) 1.02
Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2012) 1.01
Usefulness of the rendezvous technique for biliary stricture after adult right-lobe living-donor liver transplantation with duct-to-duct anastomosis. Gut Liver (2010) 1.00
Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology (2009) 1.00
ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids (2010) 1.00